. Author manuscript; available in PMC: 2012 Jun 28.

Published in final edited form as: Mucosal Immunol. 2008 Oct 29;2(1):54–62. doi: 10.1038/mi.2008.69

Table 1. Class I-restricted peptide vaccines inhibit allergic airway inflammation and skew BAL cytokine profiles.

	Allergen	Vaccine	Total cells (×10⁻³)	Eosinophils (×10⁻³)	Neutrophils (×10⁻³)	%Th1	%Th2	IFN-γ (pg/ml)	IL-5 (pg/ml)
1	PBS	PBS	53.2 ± 13.0	3.5 ± 1.1	6.1 ± 1.4	6.6 ± 0.5	0.1 ± 0.1	19.9 ± 1.7	175 ± 57.0
2	OVA	PBS	242 ± 73.2	76.3 ± 16.1	32.5 ± 5.8	5.4 ± 0.5	1.7 ± 0.2	31.0 ± 2.0	762 ± 158
3	OVA	CASAC+Anti- CD40+SIINFEKL	171 ± 38.0	32.7 ± 4.5^*	24.8 ± 4.9	6.5 ± 0.6	0.8 ± 0.2^*	186 ± 36.5^***	1662 ± 330^*
4	OVA	CASAC+peptide 25+SIINFEKL	127 ± 24.4	35.5 ± 6.2^*	23.9 ± 3.9	14.2 ± 2.1^**	0.8 ± 0.2^*	44.2 ± 4.3^*	560 ± 145

IFN-γ, interferon-γ; IL-5, interleukin-5; PBS, phosphate-buffered saline.

Infl ammatory cell numbers and cytokine profi les from BAL CD4 cells in mice sensitized (400 μg OVA/alum) and challenged with OVA, and vaccinated with SIINFEKL peptide in CASAC adjuvant containing either anti-CD40 or an irrelevant class II helper peptide (peptide 25).

P < 0.05

^**

P < 0.01

^***

P < 0.001, all in comparison to group 2. Results are from groups of 6 mice. Similar results were obtained in 3 independent experiments.